Drug Degradation Caused by <i>mce3R</i> Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis

Published:2022-10-18 Issue:10 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pi Rui¹,Chen Xiaomin¹,Meng Jian²,Liu Qingyun¹,Chen Yiwang¹,Bei Cheng¹,Wang Chuan¹,Gao Qian¹³^ORCID

Affiliation:

1. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

3. National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, Guangdong Province, China

Abstract

Contezolid (MRX-I), a safer antibiotic of the oxazolidinone class, is a promising new antibiotic with potent activity against Mycobacterium tuberculosis (MTB) both in vitro and in vivo . To identify resistance mechanisms of contezolid in MTB, we isolated several in vitro spontaneous contezolid-resistant MTB mutants, which exhibited 16-fold increases in the MIC of contezolid compared with the parent strain but were still unexpectedly susceptible to linezolid.

Funder

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01034-22

Reference53 articles.

1. World Health Organization. 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2020. Global tuberculosis report 2020. World Health Organization, Geneva, Switzerland.

3. World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland.

4. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis

5. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis;Zhang X;J Thorac Dis,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis;Antimicrobial Agents and Chemotherapy;2023-12-14

2. Transcription factor mce3R modulates antibiotics and disease persistence in Mycobacterium tuberculosis;Research in Microbiology;2023-09

3. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis;2023-06-19